We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current ELTP market cap is 205.64M. The company's latest EPS is USD 0.0188 and P/E is 10.11.
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 18M | 25.38M | 32.26M | 34.16M | 56.63M |
| Operating Income | -2.29M | 2.1M | 5.07M | 3.68M | 10.79M |
| Net Income | -2.24M | 5.09M | 8.9M | 3.56M | 20.11M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 24.96M | 26.19M | 35.15M | 40.9M | 83.65M |
| Total Liabilities | 14.3M | 10.04M | 9.93M | 11.94M | 26.07M |
| Total Equity | 10.66M | 16.15M | 25.22M | 28.96M | 57.58M |
| Year End March 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -1.79M | 3.19M | 6.51M | 3.34M | -3.28M |
| Investing | -35k | -263k | -499k | -5.74M | -810k |
| Financing | 690k | -870k | -667k | 1.7M | 3.39M |
| Market Cap | 205.64M |
| Price to Earnings Ratio | 10.11 |
| Price to Sales Ratio | 3.58 |
| Price to Cash Ratio | 28.36 |
| Price to Book Ratio | 3.52 |
| Dividend Yield | - |
| Shares Outstanding | 1.07B |
| Average Volume (1 week) | 441.23k |
| Average Volume (1 Month) | 761.03k |
| 52 Week Change | 398.25% |
| 52 Week High | 0.2119 |
| 52 Week Low | 0.037 |
| Spread (Intraday) | 0.01 (5.54%) |
| Company Name | Elite Pharmaceuticals Inc (QB) |
| Address |
321 w. winnie lane carson city, nevada 89703 |
| Website | https://www.elitepharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
